AbbVie_IU_icons_outlined_v3AbbVie_IU_icons_outlined_v3checkmarkcheckmark24C1F2D2-A1A6-4D15-982D-20E53E43CC8BAbbVie_IU_icons_outlined_v3AbbVie_IU_icons_outlined_v3AbbVie_IU_icons_outlined_v3
imm-derm-hero@2x
THE FUTURE OF ABBVIE IMMUNOLOGY:

Dermatology

AbbVie is committed to the pursuit of innovative, effective solutions for dermatology diseases with unmet needs.

Our Vision for the Future

Building on a strong foundation of historical success, we’re striving to uncover new opportunities to target immune-mediated inflammatory dermatological diseases at their source, revolutionizing treatment to free the world of debilitating skin conditions. After more than a decade of research, we’ve developed unique technologies to optimize therapeutics in the area of dermatology, and we’re focused on delivering treatments in areas of high unmet medical need and where current treatment options do not meet patient expectations.

Leading the Way

The Road Ahead

Commitment to Patients

We have a bold vision for the future: one where we have an answer for even more patients. Years of clinical studies have revealed a greater need for medical solutions to accommodate a diverse community of patients.

The Road Ahead

The Road Ahead

Guided by real patient journeys, we’re investigating three immune-mediated dermatological conditions—searching relentlessly for the best path forward. Our commitment continues with long-term investments in developing label enhancements for approved products, innovation in patient support, and a focus on high-quality education for both patients and physicians.

New Pathways

New Pathways

Our pipeline currently features two late-stage investigational compounds for dermatology patients. One is a biologic that selectively blocks IL-23, an agent linked to psoriasis and psoriatic arthritis. Another, an oral JAK1-selective inhibitor, is being explored as a new treatment for patients with atopic dermatitis and psoriatic arthritis.


Our Pathways

TNF- α

A cytokine that contributes to the induction and maintenance of the inflammatory immune response.
Learn more about related assets in our Pipeline

JAK1

An enzyme partially responsible for inappropriate activation of immune cells involved in autoimmune disorders.
Learn more about related assets in our Pipeline

IL-23

A key protein involved in skin inflammation which has been linked to an overactive immune system.
Learn more about related assets in our Pipeline

RORyT

A protein that regulates the production of other key pro-inflammatory proteins.
Learn more about related assets in our Pipeline

Committed to Dermatology

News Icon

In the News

AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
Read More

AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Read More

AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting
Read More

Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
Read More

Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies
Read More

JOIN OUR TEAM

Our team of immunology experts is focused on improving the standard of care for this generation and the next. We’re committed, curious, and passionate; and we’re hiring.

STORIES

5 Things I’ve Learned From People With An Autoimmune Disease
As a Nurse Ambassador, Mary Neumann helps people with chronic skin disease navigate their health care.

Get the Latest from AbbVie

Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.

This site uses cookies to personalize content, save your preferences and track the site’s performance. Learn more, including how to disable certain cookies on our Privacy Page. Click OK to continue.